Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

LifeStance Health (LFST) Common Equity: 2021-2025

Historic Common Equity for LifeStance Health (LFST) over the last 5 years, with Q3 2025 value amounting to $1.5 billion.

  • LifeStance Health's Common Equity rose 387.23% to $1.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 billion, marking a year-over-year increase of 387.23%. This contributed to the annual value of $1.4 billion for FY2024, which is 121.45% up from last year.
  • Latest data reveals that LifeStance Health reported Common Equity of $1.5 billion as of Q3 2025, which was up 387.23% from $1.5 billion recorded in Q2 2025.
  • LifeStance Health's Common Equity's 5-year high stood at $1.5 billion during Q4 2021, with a 5-year trough of $1.4 billion in Q4 2023.
  • Its 5-year average for Common Equity is $1.5 billion, with a median of $1.5 billion in 2023.
  • Per our database at Business Quant, LifeStance Health's Common Equity tumbled by 591.24% in 2023 and then soared by 387.23% in 2025.
  • Over the past 5 years, LifeStance Health's Common Equity (Quarter) stood at $1.5 billion in 2021, then decreased by 1.7% to $1.5 billion in 2022, then fell by 5.91% to $1.4 billion in 2023, then increased by 1.21% to $1.4 billion in 2024, then increased by 3.21% to $1.5 billion in 2025.
  • Its Common Equity stands at $1.5 billion for Q3 2025, versus $1.5 billion for Q2 2025 and $1.5 billion for Q1 2025.